DOCSLIB.ORG

Global Business Information Specialist Informa’S Book Business Has More Than 55,000 Academic Advisers 26 Directors’ Report 27 and Business Titles

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Global Business Information Specialist Informa’S Book Business Has More Than 55,000 Academic Advisers 26 Directors’ Report 27 and Business Titles Business Profile Business WHO WE ARE Business Profile 02 Annual Report & Financial Statements 2009 Our Business 03 Informa at a Glance 04 Academic Information 06 Professional & Commercial Information 08 Events & Training 10 Informa plc is a leading international provider of specialist information and services for the academic and scientific, professional and commercial business communities. Informa has some 150 offices in over 40 countries and employs approximately 8,000 staff around the world. Informa is the largest publicly-owned organiser of conferences and courses in the world with inThe Year The Year in Review 12 an output of around 8,000 events annually. Informa Financial Highlights 13 publishes over 2,100 subscription-based information Chairman’s Statement 14 services including academic journals, real-time news Chief Executive’s Review 16 Financial Review 19 R and structured databases of commercial intelligence. Board of Directors 24 eview Global Business Information Specialist Informa’s book business has more than 55,000 academic Advisers 26 Directors’ Report 27 and business titles. Corporate Governance Statement 38 Directors’ Remuneration Report 45 Corporate Responsibility 55 Financial Statements Financial Financial Statements 58 Independent Auditors’ Report – Group 59 Consolidated Income Statement 60 Consolidated Statement of Comprehensive Income 61 Consolidated Statement of Changes in Equity 62 Consolidated Statement of Financial Position 64 ”It was an extremely demanding year, Consolidated Cash Flow Statement 65 but one which brought to the fore some Notes to the Consolidated Financial of the key characteristics of Informa.” Statements 66 Independent Auditors’ Report – Company 124 Derek Mapp, Chairman Company Balance Sheet 125 See page 14 Notes to the Company Financial Statements 126 Annual Report & Financial Statements 2009 Five Year Summary 131 ”During a period of sustained economic Information Company Company Information 132 decline across the world, our Publishing Legal Notices 133 assets have performed exceptionally well.” Shareholder Information 134 Peter Rigby, Chief Executive Principal Group Offices 136 A Selection of Informa See page 16 Group Websites 137 Gubelstrasse 11 CH-6300 Zug ”These financial results demonstrate the strength Switzerland of a balanced portfolio and an ability to manage Telephone: 00 41 41 444 1344 costs proactively when demand is reduced.“ Fax: 00 41 41 444 1355 Adam Walker, Finance Director See page 19 www.informa.com This report is printed on 350gsm Lumisilk and 150gsm Lumisilk Business Profile Business WHO WE ARE Business Profile 02 Annual Report & Financial Statements 2009 Our Business 03 Informa at a Glance 04 Academic Information 06 Professional & Commercial Information 08 Events & Training 10 Informa plc is a leading international provider of specialist information and services for the academic and scientific, professional and commercial business communities. Informa has some 150 offices in over 40 countries and employs approximately 8,000 staff around the world. Informa is the largest publicly-owned organiser of conferences and courses in the world with inThe Year The Year in Review 12 an output of around 8,000 events annually. Informa Financial Highlights 13 publishes over 2,100 subscription-based information Chairman’s Statement 14 services including academic journals, real-time news Chief Executive’s Review 16 Financial Review 19 R and structured databases of commercial intelligence. Board of Directors 24 eview Global Business Information Specialist Informa’s book business has more than 55,000 academic Advisers 26 Directors’ Report 27 and business titles. Corporate Governance Statement 38 Directors’ Remuneration Report 45 Corporate Responsibility 55 Financial Statements Financial Financial Statements 58 Independent Auditors’ Report – Group 59 Consolidated Income Statement 60 Consolidated Statement of Comprehensive Income 61 Consolidated Statement of Changes in Equity 62 Consolidated Statement of Financial Position 64 ”It was an extremely demanding year, Consolidated Cash Flow Statement 65 but one which brought to the fore some Notes to the Consolidated Financial of the key characteristics of Informa.” Statements 66 Independent Auditors’ Report – Company 124 Derek Mapp, Chairman Company Balance Sheet 125 See page 14 Notes to the Company Financial Statements 126 Annual Report & Financial Statements 2009 Five Year Summary 131 ”During a period of sustained economic Information Company Company Information 132 decline across the world, our Publishing Legal Notices 133 assets have performed exceptionally well.” Shareholder Information 134 Peter Rigby, Chief Executive Principal Group Offices 136 A Selection of Informa See page 16 Group Websites 137 Gubelstrasse 11 CH-6300 Zug ”These financial results demonstrate the strength Switzerland of a balanced portfolio and an ability to manage Telephone: 00 41 41 444 1344 costs proactively when demand is reduced.“ Fax: 00 41 41 444 1355 Adam Walker, Finance Director See page 19 www.informa.com This report is printed on 350gsm Lumisilk and 150gsm Lumisilk HIGHLIGHTS, SUMMARY & OUTLOOK Financial Results £1,221.7m Adjusted operating profit growth of 1.2% despite revenue decline of 4.4% Revenue Increase in adjusted operating margin to 25.3% (2008: 23.9%) 2008: £1,278.0m Organic revenue decline of 14%; organic adjusted operating profit decline of 12% Statutory profit before tax of £96.5m (2008: £109.0m) Adjusted diluted earnings per share up to 34.3p (2008: 33.9p restated) £309.5m Statutory diluted earnings per share up to 18.8p (2008: 16.8p restated) Adjusted operating profit Free cash flow of £223.8m up 6.6% - adjusted cash conversion of 105% 2008: £305.8m Second interim dividend of 7.85p, total 2009 dividend of 11.45p (2008: 8.41p) Net debt/EBITDA ratio of 2.7 times Operational Results £261.3m Publishing performed exceptionally well – now 72% of Group adjusted operating profits Adjusted profit before tax 72% of publishing revenues delivered in digital format and 64% from subscriptions 2008: £233.4m Top 200 events, generating around 55% of events and training profits, displayed greater resilience in unprecedented times Annualised cost savings of £40m, with a restructuring cost of £27.7m 11.45p Outlook Booked and deferred income represents approximately 32% of full year revenues Total dividend (2008: 29%) 2008: 8.41p The majority of subscriptions are renewing in line with previous high rates Forward bookings for exhibitions and large scale events slightly ahead of 2009 Cost base reduced – well placed for recovery for futher information, see Financial Highlights, page 13, and FInancial Review, page 19 ® Informa at a glance OUR VALUES HOW WE OPERATE A SELEctiON OF INFORMA GROUP WEbsitES InnoVatiVE The nature of our business +40 We link leading titles and events in many sectors so target specific markets countries where that our content is the prime information source. Non-BUreaUcratic we operate We have built the business as a 3-dimensional matrix expand geographically with vertical (niche) markets on one axis, geographies on FOR Profit the second and media distribution formats on the third. +2,100 extend media distribution Open subscription-based Our business operates in three segments: information services • Academic Information Rewarding • Professional & Commercial Information MarKet-FocUsed +55,000 • Events & Training book titles published ABOUT QUality +8,000 events www.informa.com www.lifescienceanalytics.com www.iir.es +8,000 www.crcpress.com www.lloydslist.com www.iir.nl staff Revenue by type Revenue by business segment Revenue by geography www.psypress.com www.marketlineinfo.com www.iir.pl/iir www.tandf.co.uk/journals www.omega-performance.com www.iir-hungary.hu www.taylorandfrancis.com www.orbys.com www.iir-italy.it www.taylorandfrancisgroup.com www.ovumkc.com www.iirmd.com 7. 8. 6. www.r4l.info www.iirme.com 1. 3. 1.1. 4. 1. www.informaworld.com 5. www.achieveglobal.com www.robbinsgioia.com www.iir-training.co.za 4. www.agra-net.com www.scrip100.com www.iirusa.com www.ceasc.com www.scripnews.com www.informa.com.au www.datamonitor.com www.theblackbookofoutsourcing.com www.informatm.com 2. 2. 2. www.ebenchmarkers.com www.verdict.co.uk www.informaglobalevents.com 3. 3. www.esi-intl.com www.abudhabiyachtshow.com www.konference.cz www.esi-se.com www.adamsmithconferences.com www.monacoyachtshow.com www.forum.com www.arabhealthonline.com www.thesuperyachtcup.com www.cityscapeglobal.com Informa has been recognised for the second year 1. Delgates 25% 1. Academic Information £294.4m 1. United Kingdom £168.1m www.globalbusinessinsights.com www.euroforum.de running as one of Britain’s Top 100 Employers, 2. Copy sales 16% 2. Professional & 2. North America £480.8m www.huthwaite.com according to research conducted by CRF in 3. Subscriptions 35% Commercial Information £368.3m 3. Continental Europe £314.2m www.ibclifesciences.com www.futd.nl conjunction with Guardian Books. Organisations 4. Exhibition 7% 3. Events & Training £559.0m 4. Rest of World £258.6m www.iff-training.com www.ibceuroforum.dk all over Britain were judged by a panel of experts 5. Sponsorship 4% www.iirusa.com www.icbi-events.com/gaim for their performance in career development, 6. Consulting 6% www.informaecon.com www.icbi-events.com/superreturn training development, pay and benefits, working 7. Advertising 3% www.informahealthcare.com www.icbi-uk.com conditions and company culture – Informa 8. Other 4% www.informais.com www.iir.at received 5 out of 5 stars overall. www.informars.com
Load more

Recommended publications
  • Expect the Unexpected: Building Business Value in a Changing World
    Expect the Unexpected: Building business value in a changing world kpmg.com KPMG INTERNATIONAL PART 1 b | Expect the Unexpected: Building business value in a changing world In this report we offer a starting point for discussion. We present a system of ten sustainability megaforces that will impact each and every business over the next 20 years. We want to build awareness that these forces do not act alone in predictable ways. They are interconnected. They interact. Disclaimer: Throughout this document, "KPMG" ["we," "our," and "us"] refers to KPMG International, a Swiss entity that serves as a coordinating entity for a network of independent member firms operating under the KPMG name, KPMG's Climate Change and Sustainability practice, and/or to any one or more of such firms. KPMG International provides no client services. © 2012 KPMG International Cooperative (“KPMG International”), a Swiss entity. Member firms of the KPMG network of independent firms are affiliated with KPMG International. KPMG International provides no client services. All rights reserved. Expect the Unexpected: Building business value in a changing world | c Foreword usinesses today are operating in an ever more At KPMG’s network of firms we have always been at the interconnected and globalized world. Supply chains forefront of developments that shape business behavior. Bstretch across continents and are vulnerable to We are working with organizations to help them understand disruption. Consumer demands and government policies the forces at work that will influence markets and impact are changing rapidly and will impact your bottom line if your profitability in the medium to long term.
    [Show full text]
  • Genome Editing with CRISPR/Cas9 in Postnatal Mice Corrects PRKAG2 Cardiac Syndrome
    Cell Research (2016) 26:1099-1111. © 2016 IBCB, SIBS, CAS All rights reserved 1001-0602/16 $ 32.00 ORIGINAL ARTICLE www.nature.com/cr Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome Chang Xie1, 2, *, Ya-Ping Zhang3, *, Lu Song2, *, Jie Luo1, Wei Qi2, Jialu Hu3, Danbo Lu3, Zhen Yang3, Jian Zhang2, Jian Xiao1, Bin Zhou4, Jiu-Lin Du5, Naihe Jing2, Yong Liu1, Yan Wang1, Bo-Liang Li2, Bao-Liang Song1, Yan Yan3 1Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan 430072, China; 2The State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yue-Yang Road, Shanghai 200031, China; 3Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China; 4Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sci- ences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yue-Yang Road, Shanghai 200031, China; 5Institute of Neuroscience and State Key Laboratory of Neuroscience, Shanghai Institutes for Biological Sciences, Chinese Acade- my of Sciences, 320 Yue-Yang Road, Shanghai 200031, China PRKAG2 cardiac syndrome is an autosomal dominant inherited disease resulted from mutations in the PRK- AG2 gene that encodes γ2 regulatory subunit of AMP-activated protein kinase. Affected patients usually develop ventricular tachyarrhythmia and experience progressive heart failure that is refractory to medical treatment and requires cardiac transplantation. In this study, we identify a H530R mutation in PRKAG2 from patients with famil- ial Wolff-Parkinson-White syndrome. By generating H530R PRKAG2 transgenic and knock-in mice, we show that both models recapitulate human symptoms including cardiac hypertrophy and glycogen storage, confirming that the H530R mutation is causally related to PRKAG2 cardiac syndrome.
    [Show full text]
  • 2015 Informa Investor Day
    2015 Informa Investor Day 18 November 2015 INTRODUCTION STEPHEN A. CARTER GROUP CHIEF EXECUTIVE 2015 Informa Investor Day Presentation Schedule • Introduction • Academic Publishing – Content Depth and Operating Efficiency • Global Exhibitions – Maximising the Growth Opportunity • Greenbuild – Overview & Tour • Lunch • Operational & Financial Update • Summary and Q&A THE JOURNEY SO FAR Stephen Carter appointed 2014 Investor Day Group CEO & launch of Disposal of Consumer Info. strategic review Review of strategic options for European Conferences Gareth Wright confirmed as Group FD, external appointment of BI and K&N Dwell acquisition FIME acquisition CEO’s 2013 2016 2014-2017 Growth Hanley Wood Disposal of Acceleration Plan Exhibitions acquisition Scandinavian announced and placing Conferences New operating Virgo acquisition Orlando Megacon Disposal of Dutch structure announced acquisition Conferences INFORMA GROUP INVESTOR DAY NOVEMBER 2015 4 2014-2017 GROWTH ACCELERATION PLAN FRAMEWORK Growth Acceleration Plan GAP GAP GAP GAP GAP GAP Operating Management Portfolio Acquisition Investment Funding Structure Model Management Strategy • 4 Operating Divisions • EMT established • Consumer Info disposal • Hanley Wood Exhib. • £70-90m programme • Renegotiated RCF • Global Support • Divisional SMTs • InsuranceIQ disposal • Virgo • 30-40 projects • $250m PPP issue • Medical Journals transfer • GE succession • Chinese Pharma closure • Orlando Megacon • 21 projects underway • Group Treasurer • WPA and Learning transfer • 3 yr business plans • Closure
    [Show full text]
  • Novartis Swaps Two Avexis Executives for One Following
    No. 3969 August 23, 2019 and CSO that the Kaspars have not been involved in the Novartis subsidiary’s op- erations since early May. Asked whether more AveXis employees will exit the company due to the preclini- cal safety data manipulation revealed on 6 August or whether other actions will be taken by Novartis in relation to the matter, Althoff told Scrip: “We cannot comment on the specifics of who is involved, but we can confirm this issue was not widespread, ei- ther in our overall dataset nor in our com- pany or any function within our company and was limited to a few individuals.” Novartis CEO Vas Narasimhan said in a 7 August conference call about the Zol- gensma data controversy that the compa- ny was in the process of “exiting the small number of AveXis scientists involved” in the data manipulation, which occurred Novartis Swaps Two AveXis before Novartis bought the gene therapy firm. (Also see “Novartis CEO Explains De- lay In Telling US FDA About Zolgensma Executives For One Following Data Fraud: We Wanted To Understand It First” - Pink Sheet, 7 Aug, 2019.) Zolgensma Data Manipulation Novartis acquired AveXis for $8.7bn MANDY JACKSON [email protected] last year. (Also see “Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisi- ovartis AG said when it disclosed the Zolgensma BLA was manipulated. Page tion” - Scrip, 9 Apr, 2018.) Zolgensma was that preclinical safety data for Zol- Bouchard, whose most recent function was the lead asset in AveXis’s R&D pipeline and Ngensma were manipulated in the bi- global head of preclinical safety for Novar- won US Food and Drug Administration ologic license application for the gene ther- tis Institutes of Biomedical Research (NIBR), approval in May, becoming the world’s apy that the company would be “exiting” was named senior vice president and chief most expensive drug with a $2m list price.
    [Show full text]
  • Parker Review
    Ethnic Diversity Enriching Business Leadership An update report from The Parker Review Sir John Parker The Parker Review Committee 5 February 2020 Principal Sponsor Members of the Steering Committee Chair: Sir John Parker GBE, FREng Co-Chair: David Tyler Contents Members: Dr Doyin Atewologun Sanjay Bhandari Helen Mahy CBE Foreword by Sir John Parker 2 Sir Kenneth Olisa OBE Foreword by the Secretary of State 6 Trevor Phillips OBE Message from EY 8 Tom Shropshire Vision and Mission Statement 10 Yvonne Thompson CBE Professor Susan Vinnicombe CBE Current Profile of FTSE 350 Boards 14 Matthew Percival FRC/Cranfield Research on Ethnic Diversity Reporting 36 Arun Batra OBE Parker Review Recommendations 58 Bilal Raja Kirstie Wright Company Success Stories 62 Closing Word from Sir Jon Thompson 65 Observers Biographies 66 Sanu de Lima, Itiola Durojaiye, Katie Leinweber Appendix — The Directors’ Resource Toolkit 72 Department for Business, Energy & Industrial Strategy Thanks to our contributors during the year and to this report Oliver Cover Alex Diggins Neil Golborne Orla Pettigrew Sonam Patel Zaheer Ahmad MBE Rachel Sadka Simon Feeke Key advisors and contributors to this report: Simon Manterfield Dr Manjari Prashar Dr Fatima Tresh Latika Shah ® At the heart of our success lies the performance 2. Recognising the changes and growing talent of our many great companies, many of them listed pool of ethnically diverse candidates in our in the FTSE 100 and FTSE 250. There is no doubt home and overseas markets which will influence that one reason we have been able to punch recruitment patterns for years to come above our weight as a medium-sized country is the talent and inventiveness of our business leaders Whilst we have made great strides in bringing and our skilled people.
    [Show full text]
  • Ascential Secure
    Ascential Secure Enhanced Health & Safety Standards at Ascential’s Events in a Post-COVID-19 World 1 ​ About Ascential Secure Ascential Secure is our approach to enhanced health and safety standards at our events following COVID-19. From exhibitors to sponsors, speakers, visitors and journalists, those who come to our events do so to gain the information, insights, connections, data and digital tools that they need, effectively and safely. The standards and practices that make up Ascential Secure are designed to provide confidence that at every Ascential event, we are striving to provide the highest standards of safety, hygiene, cleanliness and quality. Whether they are exhibitors, attendees, visitors, speakers or sponsors, people come to events to connect, learn, know more and do more business, effectively, safely and with confidence. Ascential Secure is based on a set of event industry standards, called AllSecure. The AllSecure industry standards were developed collaboratively by a group including industry associations UFI, AEO and SISO, event organisers Informa, Reed Exhibitions and Clarion, a range of event venues, suppliers and with input from health, government and local authorities. Ascential Secure is the way these industry-wide AllSecure standards are being applied to Ascential live events. You can expect to see that health and safety continues to be a priority, and that a range of measures are in place to ensure everyone involved is able to enjoy a safe, hygienic, productive and high-quality organised event experience. As a starting point, Ascential Secure events will be run according to the guidance of the government or official local authority for that location, and according to any venue-specific regulations.
    [Show full text]
  • [ "Pearson F-1 Rights Offering" ]
    As filed with the Securities and Exchange Commission on August 8, 2000 Registration No. 333-43198 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PEARSON plc (Exact name of registrant as specified in its charter) England and Wales 2731 Not Required (State or other jurisdiction (Primary Standard Industrial (I.R.S. Employer of incorporation or organization) Classification Code Number) Identification Number) 3 Burlington Gardens Pearson Inc. London, England W1X 1LE 1330 Avenue of the Americas 44-20-7411-2000 New York, New York 10019 (Address, including zip code, and telephone number, (212) 641-2400 including area code, of registrant's principal executive (Name, address, including zip code, and telephone number, offices) including area code, of agent for service) Copies to: Charles E. Engros Robert M. Thomas, Jr. Morgan, Lewis & Bockius LLP Sullivan & Cromwell 101 Park Avenue 125 Broad Street New York, New York 10178 New York, New York 10004 (212) 309-6000 (212) 558-4000 Fax: (212) 309-6273 Fax: (212) 558-3588 Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ፤ If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
    [Show full text]
  • Annual Report 2020
    In pursuit of progress since Annual report 2020 report Annual Annual report 2020 In pursuit of progress since Annual report 2020 report Annual Annual report 2020 CONTENTS ANNUAL REPORT STRATEGIC REPORT 2 Five-year summary 3 Group overview 4 From the chairman 6 From the chief executive 8 From the editor 9 Business review: the year in detail 13 The Economist Educational Foundation 15 The Economist Group and environmental sustainability 17 Corporate governance: the Wates Principles, our Section 172(1) statement and our guiding principles REPORT AND ACCOUNTS GOVERNANCE 22 Directors 23 Executive team 24 Trustees, board committees 25 Directors’ report 28 Directors’ report on remuneration 31 Financial review CONSOLIDATED FINANCIAL STATEMENTS 35 Independent auditor’s report to the members of The Economist Newspaper Limited 38 Consolidated income statement 39 Consolidated statement of comprehensive income 40 Consolidated balance sheet 41 Consolidated statement of changes in equity 42 Consolidated cashflow statement 44 Notes to the consolidated financial statements COMPANY FINANCIAL STATEMENTS 94 Company balance sheet 95 Company statement of changes in equity 96 Notes to the company financial statements NOTICES 108 Notice of annual general meeting 1 STRATEGIC REPORT Five-year summary 2020 2019 2018 2017 2016 £m £m £m £m £m Income statement—continuing business* Revenue 326 333 329 303 282 Operating profit 31 31 38 43 47 Profit after taxation 21 25 28 39 37 Profit on sale of CQ-Roll Call, Inc - 43 - - - Profit on sale of Economist Complex - - - -
    [Show full text]
  • Annual Report 2012
    BRINGING How we have performed KNOWLEDGE FIN ANCIAL HIGHLIGHTS • Record adjusted diluted EPS up 7.7% to 40.7p (2011: 37.8p), ahead of market expectations TO LIFE • Full year dividend increased by 10.1% – second interim dividend of 12.5p giving a total 2012 dividend of 18.5p (2011: 16.8p) Businesses, professionals and • Revenue broadly flat despite Robbins Gioia and European academics worldwide turn to Informa Conference disposals – £1.23bn (2011: £1.28bn) for unparalleled knowledge, up-to- • Adjusted operating profit up 4.0% to £349.7m the minute information and highly (2011: £336.2m); organic growth of 2.8% specialist skills and services. • Record adjusted operating margin of 28.4% (2011: 26.4%) Our ability to deliver high quality • Adjusted profit before tax of £317.4m up 7.3% (2011: £295.9m) knowledge and services through • Statutory profit after tax of £90.7m (2011: £74.3m) multiple channels, in dynamic and rapidly changing environments, • Strong cash generation – operating cash flow up 5.7% to £329.0m (2011: £311.2m) makes our offer unique and • Balance sheet strength maintained – net debt/EBITDA extremely valuable to individuals ratio of 2.1 times (2011: 2.1 times) and organisations. OPEAI R T ONAL HIGHLIGHTS • Proactive portfolio management drives significant Annual Report & Financial Statements for the year ended December 31 2012 improvement in the quality of Group earnings • Total product rationalisation reduced Group revenue by 2% • Investment in new products, geo-cloning and platform development • Acquisition of MMPI and Zephyr
    [Show full text]
  • Strategic Orientation Document for Malaria Vector Surveillance and Control in Latin America and the Caribbean
    Amazon Malaria Initiative/ Amazon Network for the Surveillance of Antimalarial Drug Resistance Strategic Orientation Document for Malaria Vector Surveillance and Control in Latin America and the Caribbean INICIATIVA AMAZÓNICA CONTRA LA MALARIA/ RED AMAZÓNICA DE VIGILANCIA DE LA RESISTENCIA A LOS ANTIMALÁRICOS Documento estratégico para la gestión del suministro y garantía de la calidad de los medicamentos e insumos para el diagnóstico y tratamiento de la malaria Recommended Citation: US Centers for Disease Control and Prevention (CDC), Pan American Health Organization (PAHO/WHO), and RTI. 2011. Strategic Orientation Document for Malaria Vector Surveillance and Control in La tin America and the Caribbean. Submitted to the U.S. Agency for International Development by the CDC and Links Media, LLC. Gaithersburg, MD. Available at http://www.usaidami.org/resources.shtml Amazon Malaria Initiative/ Amazon Network for the Surveillance of Antimalarial Drug Resistance TABLE OF CONTENTS 1. Glossary / 5 2. Acronyms and abbreviations / 6 3. Objective / 7 4. Introduction / 9 5. Vector control / 11 5.1 Indoor residual spraying / 12 5.2 Insecticide-treated nets / 13 5.3 Source reduction / 14 5.4 Integrated vector management / 15 6. Vector surveillance / 17 6.1 Entomological surveillance / 18 6.2 Monitoring vector control operations / 22 6.3 Entomological indicators / 23 6.4 Operational indicators / 25 7. Monitoring plans per epidemiological strata / 29 7.1 Moderate to low-transmission settings / 29 7.2 Low to very low-transmission settings / 31 7.3 Settings with no active transmission but risk of transmission / 33 8. References / 35 9. Annexes / 39 Annex 1: Malaria vectors in the Americas / 39 Annex 2: WHO recommended insecticides for indoor residual spraying / 40 Annex 3: WHO recommended long-lasting insecticide-treated nets / 41 Strategic Orientation Document for Malaria Vector Surveillance and Control in Latin America and the Caribbean 3 About this document: This document was produced through the Amazon Malaria Initiative (AMI) and was financed by the U.S.
    [Show full text]
  • Wolters Kluwer Governance Roadshow
    Wolters Kluwer Governance Roadshow Selection & Remuneration Committee of the Supervisory Board of Wolters Kluwer September, 2020 Governance Roadshow, September 2020 1 Forward-looking statements This presentation contains forward-looking statements. These statements may be identified by words such as "expect", "should", "could", "shall", and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions, conditions in the markets in which Wolters Kluwer is engaged, behavior of customers, suppliers and competitors, technological developments, the implementation and execution of new ICT systems or outsourcing, legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions and divestments. In addition, financial risks, such as currency movements, interest rate fluctuations, liquidity and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Growth rates are cited in constant currencies unless otherwise noted.
    [Show full text]
  • Informa 2018 Full Year Results Statement
    Informa LEI: 5493006VM2LKUPSEDU20 Press Release 7 March 2019 Informa PLC Results for 12 Months to 31 December 2018 2018: Combination & Creation 2019: Performance & Growth KEY FINANCIAL AND OPERATING HIGHLIGHTS1 • Strong Revenue Growth: +3.7% underlying and +34.9% reported to £2,369.5m, including six months of UBM (2017: £1,756.8m) • Higher Adjusted Operating Profit: +2.3% underlying and +34.4% reported to £732.1m (2017: £544.9m) • Improved Statutory Operating Profit: £363.2m (2017: £344.7m) • Increased Adjusted Diluted Earnings per Share: +7.0% to 49.2p (2017: 46.0p); Statutory EPS of 19.7p (2017: 37.6p), with prior year including non-cash credit from US tax reforms • Attractive Free Cash Flow: £503.2m and £600m+ including a full year of UBM (2017: £400.9m) • Robust Balance Sheet, in line with plan: Net debt/EBITDA1 at 2.9x (2017: 2.5x) • Enhanced Dividend: up 7.1% to 21.90p (2017: 20.45p) London: Informa (LSE: INF.L), the International Exhibitions, Events, Information Services and Scholarly Research Group, today published its financial results for the 12 months to 31 December 2018, reporting a further period of operational progress and improving financial performance. Stephen A. Carter, Group Chief Executive, said: “In 2018, the Informa Group delivered a fifth consecutive year of improving growth, increasing adjusted profits, adjusted earnings per share, cashflow and dividends.” He added: “In 2019, our focus is on continuing Performance and Growth as we consolidate our market positions and further reduce complexity. This will enable
    [Show full text]